159 related articles for article (PubMed ID: 15519508)
21. [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
Drouet L
Pathol Biol (Paris); 2008 Jun; 56(4):195-204. PubMed ID: 18450388
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
23. [Refractory anaemia successfully treated with thalidomide].
Hansen M; Hansen PB
Ugeskr Laeger; 2006 Feb; 168(6):591-2. PubMed ID: 16476224
[TBL] [Abstract][Full Text] [Related]
24. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma.
Ben M'barek L; Fardet L; Mebazaa A; Thervet E; Biet I; Kérob D; Morel P; Lebbe C
Dermatology; 2007; 215(3):202-5. PubMed ID: 17823515
[TBL] [Abstract][Full Text] [Related]
25. Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Yang Y; Ge JP; Zhou ZT
J Oral Pathol Med; 2009 May; 38(5):455-62. PubMed ID: 19141066
[TBL] [Abstract][Full Text] [Related]
26. Clinical trials referral resource. Current clinical trials of thalidomide.
Streicher HZ; Vereshchagina LA; Schoenfeldt M
Oncology (Williston Park); 2003 Mar; 17(3):369-71, 374-5, 379-80. PubMed ID: 12661268
[No Abstract] [Full Text] [Related]
27. Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children.
López-Aguilar E; Sepúlveda-Vildósola AC; Betanzos-Cabrera Y; Rocha-Moreno YG; Gascón-Lastiri G; Rivera-Márquez H; Wanzke-del-Angel V; Cerecedo-Díaz F; de la Cruz-Yañez H
Arch Med Res; 2008 Oct; 39(7):655-62. PubMed ID: 18760193
[TBL] [Abstract][Full Text] [Related]
28. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide: an old sedative-hypnotic with anticancer activity?
Gasparini G; Morabito A; Magnani E; Gattuso D; Capaccetti B; Alberti AM
Curr Opin Investig Drugs; 2001 Sep; 2(9):1302-8. PubMed ID: 11717819
[TBL] [Abstract][Full Text] [Related]
30. Thrombosis associated with angiogenesis inhibitors.
Elice F; Rodeghiero F; Falanga A; Rickles FR
Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
[TBL] [Abstract][Full Text] [Related]
31. Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.
Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J
Int J Exp Pathol; 2002 Apr; 83(2):99-104. PubMed ID: 12084046
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
Ramasamy K; Lim Z; Pagliuca A; Salisbury JR; Mufti GJ; Devereux S
Haematologica; 2006 Aug; 91(8 Suppl):ECR44. PubMed ID: 16923528
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide makes a comeback.
Dodd-Butera T; Broderick M
RN; 2003 May; 66(5):32-5; quiz 36. PubMed ID: 12778690
[No Abstract] [Full Text] [Related]
34. [Thalidomide and cancer--revival of a drug].
Leibovici D; Lindner A
Harefuah; 2001 Jun; 140(6):524-7. PubMed ID: 11420856
[No Abstract] [Full Text] [Related]
35. Thalidomide: a role in oral oncology?
Porter SR; Jorge J
Oral Oncol; 2002 Sep; 38(6):527-31. PubMed ID: 12167429
[TBL] [Abstract][Full Text] [Related]
36. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Kerbel RS
Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
[TBL] [Abstract][Full Text] [Related]
38. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
39. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
Murphy S; Boyle FM; Davey RA; Gu XQ; Mather LE
J Pharm Pharmacol; 2007 Jan; 59(1):105-14. PubMed ID: 17227627
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?
Ozkan M; Eser B; Er O; Dogu GG; Altinbas M
J Clin Oncol; 2005 Mar; 23(9):2113; author reply 2113-4. PubMed ID: 15774812
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
